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Sir,
Hypertension is the leading attributable risk factor formortality in the global burden of cardiovascular diseases(CVD).1 Role of aspirin has been under debate in thepast decade. In contrast, in a recent systematic reviewpublished in 2015 on 103,787 patients, reported risk ofmajor gastrointestinal bleeding was increased and riskof hemorrhagic stroke or other intracranial bleedingtended to be increased in primary prevention trials inpatients on aspirin.2
In many large trials which were conducted, the use ofaspirin and cardiovascular outcomes on South-Asianpopulation was not represented although they arerelatively at higher risk of CVD.3 Hence, aspirin use forprevention of CVD may have different results (bothbeneficial and adverse outcomes). So, the objective ofthis study is to determine the impact of aspirin use oncardiovascular disease including myocardial infarction(MI/angina and stroke) in hypertensive patients.
We did a cross-sectional study conducted in theDepartment of Medicine, The Aga Khan UniversityHospital, Karachi, Pakistan over a 3-year period from2010 to 2012. Ethical clearance was taken from theEthics Review Committee of The Aga Khan University(2827-Med-ERC-13). All participants aged greater than40 years with history of hypertension, admitted throughemergency room with MI/angina or stroke, wererecruited. History of using aspirin was recorded.Hypertension was defined as SBP >140 mm Hg andDBP >90 mm Hg.4 Use of aspirin defined as using aminimum dose of 75-81 mg of aspirin for minimum 4weeks prior to ER visit was recorded.
A total of 575 patients were included in the study. Meanage was 63.96 +11.67 years, of which 372 (64.7%) weremales and 203 (35%) were females. Aspirin use waspresent in 330 (57.4%) patients. Out of the 343 (59.7%)who had MI/angina, 208/343 (60.6%) were on aspirin forupto one month prior to the ER visit. Out of the 193(33.6%) stroke patients, 99/193 (51.3%) were on aspirin.Upper gastrointestinal bleeding occurred in 49 (8%)patients and 26 (4.5%) were on aspirin. The OR of use
of aspirin with myocardial infarction/angina and stroke isreported in Table I.Use of aspirin did not show a clear benefit in primaryprevention for ischemic heart diseases (IHD) and strokein this hypertensive patient population. This concept hasremained a topic of debate in the last decade. As use ofaspirin in secondary prevention of IHD and stroke is wellestablished in the high-risk prevalent atheroscleroticcardiovascular diseases including IHD and stroke,aspirin decreases acute CVD event (approximately 20%reduction in coronary events and total stroke).5 This studydemonstrated that there is no clear role of aspirin inprimary prevention of IHD or stroke in hypertensivepatients. Hence, we conclude that aspirin has no clearrole in primary prevention of IHD or stroke in hypertensivepatients; and this effect is irrespective of age and gender.However, more studies are required to further confirmthis conclusion as this study has limited external validity.
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Table I: Association of aspirin use with ischemic heart disease and stroke adjusted for covariates.
Aspirin used N (%) Crude OR 95% CI p-value Adjusted model * p-value Adjusted Model** p-value
OR 95% CI OR 95% CI 
208 (60.6) Ischemic heart disease (N=343)
0.76 (0.5,1.0) 0.06 0.72 (0.5,1.0) 0.06 0.8 (0.51,1.2) 0.3 
99 (51.3) Stroke (N=193)
0.69 (0.49,0.9) 0.04 0.7 (0.49,1.0) 0.7 0.7 (0.5,1.1) 0.2 *Adjusted for age and gender **Adjusted for prior history of myocardial infarction, stroke, diabetes , dyslipidemia and chronic kidney disease.
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